PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA

Authors
LAW TM ILSON DH MOTZER RJ
Citation
Tm. Law et al., PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA, Investigational new drugs, 12(2), 1994, pp. 143-145
Citations number
5
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
12
Issue
2
Year of publication
1994
Pages
143 - 145
Database
ISI
SICI code
0167-6997(1994)12:2<143:PTOTIP>2.0.ZU;2-U
Abstract
Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the mos t common toxicity. Eighty percent (12 of 15) of patients experienced g rade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.